• Treatment of wild-type RAS (wild type in KRAS and NRAS) metastatic colorectal cancer that has failed fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy (to be used as monotherapy).
• Treatment of wild-type RAS (wild type in KRAS and NRAS) metastatic colorectal cancer (as first-line therapy with FOLFOX).

Contraindicated in:

• Concurrent use of leucovorin
• RAS: mutant metastatic colorectal cancer or unknown RAS mutation status (↑ mortality and tumor progression)
• OB: Pregnancy
• Lactation: Lactation.

Use Cautiously in:

• Rep: Women of reproductive potential
• Pedi: Safety and effectiveness not established in children.

CV: edema.

Derm: acneiform dermatitis, dry skin, erythema, paronychia, pruritus, rash, skin exfoliation, skin fissures, abscesses, NECROTIZING FASCIITIS, photosensitivity.

EENT: corneal perforation, eyelash growth, keratitis, ulcerative keratitis.

F and E: hypocalcemia, hypomagnesemia.

GI: abdominal pain, constipation, diarrhea, nausea, vomiting, stomatitis.

GU: acute renal failure.

Neuro: fatigue.

Resp: cough, INTERSTITIAL LUNG DISEASE (ILD), PULMONARY FIBROSIS.

Misc: INFUSION REACTIONS, SEPSIS.

Drug-Drug:

• None reported.

• Solution for injection: 20 mg/mL;

• IV (Adults): 6 mg/kg every 14 days.

Vectibix

• Binds to epidermal growth factor receptor resulting in inactivation of kinases that regulate proliferation and transformation.

• Decreased progression of colorectal cancer.

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-life: 7.5 days.

(plasma concentrations)

• Explain purpose of panitumumab to patient.
• May cause photosensitivity. Caution patient to wear sunscreen and hats and to limit sun exposure.
• Advise patient to notify health care professional if signs and symptoms of dermatologic toxicity, infusion reactions, pulmonary fibrosis, or ocular changes occur.
• Rep: May cause fetal harm. Advise females of reproductive potential to use effective contraception and to avoid breastfeeding during and for 2 months after last dose. May impair fertility in females.
• Emphasize the need for periodic blood tests to monitor electrolyte levels.

pan-i-TU-mu-mab

NDC Code^*

• 55513- Amgen Inc
  • 55513-954- Vectibix
    • 55513-954-01- 1 VIAL, SINGLE-DOSE in 1 CARTON (55513-954-01) > 5 mL in 1 VIAL, SINGLE-DOSE

• 55513- Amgen Inc
  • 55513-956- Vectibix
    • 55513-956-01- 1 VIAL, SINGLE-DOSE in 1 CARTON (55513-956-01) > 20 mL in 1 VIAL, SINGLE-DOSE